Introduction
============

Lung cancer is the most common malignant tumor and the leading cause of cancer-related death in the world.[@b1-ott-8-2033] More than 1.5 million new cases of lung cancer are diagnosed every year, approximately 80% of which are non-small cell lung cancer (NSCLC).[@b2-ott-8-2033] The morbidity is rapidly increasing mainly due to environmental pollution and unhealthy lifestyles (eg, smoking, occupational exposure, diet).[@b3-ott-8-2033] Although surgery is the recommended treatment for NSCLC, only one-third of patients are suitable for surgery when they are diagnosed.[@b4-ott-8-2033] Unfortunately, 5-year overall survival (OS) rate of all stages is approximately 11%--15%.[@b5-ott-8-2033],[@b6-ott-8-2033] Even among early stage (I/II) NSCLC patients who only undergo surgical resection, the 5-year OS rate is just 45.1%.[@b7-ott-8-2033] These rates indicate that postoperative treatment strategies (eg, chemotherapy, radiotherapy) are essential to improve NSCLC patients' prognosis.

Chemotherapy plays a crucial role in comprehensive NSCLC therapy. Currently, cisplatin-based drugs are the most widely used chemotherapy medicine for NSCLC. Additionally, tegafur--uracil (UFT) is another oral chemotherapy agent popular in Japan because it is associated with mild toxicity. It has been demonstrated that chemotherapy regimens based on these two drug types can significantly improve the prognosis of advanced stage (III/IV) NSCLC patients.[@b8-ott-8-2033]--[@b10-ott-8-2033] However, whether they are beneficial for early stage (I/II) NSCLC patients still remains controversial, especially for stage I patients.[@b10-ott-8-2033]--[@b15-ott-8-2033] For instance, the updated NCIC-JBR10[@b15-ott-8-2033] data with a median follow-up of 9.3 years demonstrated that cisplatin-based chemotherapy improved the survival of stage IB--II patients by 11%, and subgroup analysis showed that the survival advantage was maintained in stage II patients, but not in stage IB disease. But trials conducted by Roselli et al[@b14-ott-8-2033] indicated that postoperative cisplatin-based chemotherapy significantly improved survival of stage IB patients. Similarly, randomized controlled trials (RCTs) on postoperative chemotherapy with UFT performed by the North-east Japan Study Group for Lung Cancer Surgery (NJSG)[@b11-ott-8-2033] and Japan Lung Cancer Research Group (JLCRG)[@b12-ott-8-2033] also reached opposing conclusions.

Radiotherapy is also a widely used technology in cancer treatment. A previous meta-analysis[@b16-ott-8-2033] showed that postoperative radiotherapy had a detrimental effect on survival. However, most of the current studies combined chemotherapy and radiotherapy simultaneously, such as the famous ALPI[@b17-ott-8-2033] and IALT[@b18-ott-8-2033] studies. The only study on postoperative chemotherapy alone was conducted by NSCLC Meta-analyses Collaborative Group and utilized many outdated regimens.[@b19-ott-8-2033] Therefore, the effect of modern postoperative chemotherapy alone in NSCLC is unclear. Herein, we performed a new meta-analysis to investigate the survival benefits conferred by adjuvant chemotherapy without radiotherapy in early stage NSCLC patients.

Patients and methods
====================

Search strategy and eligibility criteria
----------------------------------------

Eligible RCTs that compared surgery plus postoperative chemotherapy versus surgery alone and published in English language were identified by searching the PubMed (<http://www.ncbi.nlm.nih.gov/pubmed>), Embase (<http://www.embase.com/info/helpfiles/>), and Science Direct (<http://www.elsevier.com/online-tools/sciencedirect>) databases. We also manually searched the reference lists of relevant meta-analyses and reviews. The keywords included: "non-small cell lung cancer", "surgery", "resection", "lobectomy", "pleurectomy", "chemotherapy", "adjuvant", "therapy", "early", "I", "II", "1", "2", and "random\*". Eligible patients had to meet the following criteria: 1) histologically confirmed NSCLC (including adenocarcinoma, squamous cell carcinoma, and large cell carcinoma) with radically resection; 2) pathologic stage I and/or II with an Eastern Cooperative Oncology Group performance status of 2 or less; 3) no major organ (liver, kidney, or heart) dysfunction; 4) no preoperative anticancer treatment; 5) no other cancer site besides lung; and 6) randomly assigned to surgery followed by adjuvant chemotherapy (chemotherapy group) and surgery alone (control group). Trials that evaluated other adjuvant therapies (radiotherapy, endocrine therapy, and immunotherapy) and neoadjuvant therapy were excluded from this meta-analysis. To update the data, RCTs published in a previous meta-analysis[@b20-ott-8-2033] in 1995 were excluded from this study; only RCTs published after January 1, 1992 were enrolled.

Data extraction
---------------

Two reviewers (Yuan-Yuan Chen and Lin-Wei Wang) independently extracted the following data from each enrolled trial: publication year, first author, pathologic stage, median follow-up time, treatment compliance, number of patients, chemotherapy regimen, and toxicity data. If provided in the trial, the *P*-value and hazard ratio (HR) at 5 years obtained from Cox regression model were used directly in this meta-analysis. If not available, approximations of HR estimates were indirectly calculated based on the correlative statistics (number of observed and total events, *P*-value, 95% confidence interval \[CI\]) using the methods described by Tierney et al.[@b21-ott-8-2033] Alternatively, data was extracted from published Kaplan--Meier curves. To further analyze the effects of prognostic factors on survival, subgroup analyses were carried out according to pathologic stage and adjuvant therapy type. Any discrepancy was resolved by discussing with another author (Bi-Bo Wu).

Quality assessment
------------------

The quality of the included RCTs was evaluated using the Cochrane Collaboration's risk of bias tool,[@b22-ott-8-2033] which included adequate sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective outcome reporting, and other bias. Each item was classified as low, high, and unclear risk of bias, and then a summary assessment of each included trial was graded as A, B, or C. Two reviewers concurrently checked the risk of bias.

Statistical analysis
--------------------

Review Manager (Version 5.2; The Cochrane Collaboration, Copenhagen, Denmark) was used for statistical analysis. Selection of fixed-effects or random-effects model was determined by statistical heterogeneity among the included trials, which was evaluated using the chi-square test and quantified using *I*^2^ statistic. The existence of homogeneity was considered unreasonable for *I*^2^\>50% and *P*\<0.10. In general, HR \>1 implied that the chemotherapy group had worse prognosis than the control group. Comparisons between cisplatin-based and single UFT chemotherapy used indirect treatment comparison (ITC) software (Version 1.0; Canadian Agency for Drugs and Technologies in Health, Ottawa, Canada) proposed by Bucher et al[@b23-ott-8-2033] which estimated the relative effects of treatment A and treatment C through the common control treatment B. Finally, publication bias was evaluated by funnel plots and further quantified by Begg's and Egger's tests[@b24-ott-8-2033],[@b25-ott-8-2033] with STATA software (Version 12.0; StataCorp LP, College Station, TX, USA). Sensitivity analysis was also conducted using STATA. Two-sided *P*-value \<0.05 was considered statistically significant.

Results
=======

Characteristics of included RCTs
--------------------------------

There were 580 trials searched from databases and six from relative references lists. We identified 25 potentially eligible trials, eleven of which were excluded from our meta-analysis, including four trials that lacked survival data regarding early stage NSCLC, five trials where patients received postoperative chemotherapy plus radiotherapy, and two trials that were published previously[@b26-ott-8-2033],[@b27-ott-8-2033] but had been updated afterward.[@b15-ott-8-2033],[@b28-ott-8-2033] Finally, 14 RCTs with 3,923 patients (chemotherapy group: 1,987 patients; control group: 1,936 patients) were included in this analysis.[@b11-ott-8-2033]--[@b15-ott-8-2033],[@b28-ott-8-2033]--[@b36-ott-8-2033] Two chemotherapy groups were separately compared with the same control group in a study by Imaizumi et al[@b32-ott-8-2033]; so we treated this trial as two independent studies. To avoid repeat counting, the control group in these two studies was counted once in the analytical process. The screening process was briefly shown in [Figure 1](#f1-ott-8-2033){ref-type="fig"}. The available median follow-up time and chemotherapy compliance were ranged from 51 to 120 months and 53% to 86%, respectively. The baseline characteristics of chemotherapy group and control group are balanced and summarized in [Table 1](#t1-ott-8-2033){ref-type="table"}.

All RCTs included a statement about randomization, and detailed descriptions were listed in eleven trials. Blinding of participants and personnel assessment was only described in one trial.[@b14-ott-8-2033] However, it was not always feasible to blind in studies involving surgery. No quality difference was observed in the included RCTs except for in the study of Strauss et al[@b35-ott-8-2033] which had a higher risk than others due to early termination (data not shown).

Overall analysis of survival
----------------------------

Data for 5-year disease-free survival (DFS) was available in eleven trials[@b11-ott-8-2033],[@b12-ott-8-2033],[@b14-ott-8-2033],[@b28-ott-8-2033],[@b29-ott-8-2033],[@b31-ott-8-2033]--[@b33-ott-8-2033],[@b35-ott-8-2033]--[@b37-ott-8-2033] with a total of 2,937 patients. Although six trials[@b11-ott-8-2033],[@b12-ott-8-2033],[@b28-ott-8-2033],[@b35-ott-8-2033]--[@b37-ott-8-2033] showed that DFS was not significantly increased in chemotherapy group, the combined analysis displayed that survival benefit was achieved with postoperative chemotherapy (*P*=0.005; [Figure 2A](#f2-ott-8-2033){ref-type="fig"}), and the recurrence risk was greater in the control group compared to the chemotherapy group (41.3% versus 32.2%). Because significant heterogeneity existed among trials (*I*^2^=71%), random-effects model was adopted and achieved a combined HR of 0.71 (95% CI, 0.57--0.90). There was evidence of publication bias by Egger's test (*P*=0.029).

There were 13 trials[@b11-ott-8-2033]--[@b15-ott-8-2033],[@b28-ott-8-2033]--[@b35-ott-8-2033] (3,656 patients) with complete OS information. The analysis showed that the survival of chemotherapy group was significantly better than control group without heterogeneity in trials (*P*\<0.00001, *I*^2^=0%). The combined HR with fixed-effects model was 0.74 (95% CI, 0.67--0.83; [Figure 2B](#f2-ott-8-2033){ref-type="fig"}), which represented a 26% relative reduction of death risk in chemotherapy group. No publication bias was detected by Begg's and Egger's tests.

Subgroup analysis of survival by stage
--------------------------------------

Eight trials[@b12-ott-8-2033],[@b14-ott-8-2033],[@b28-ott-8-2033],[@b31-ott-8-2033]--[@b33-ott-8-2033],[@b35-ott-8-2033],[@b36-ott-8-2033] (2,833 patients) allowed for a quantitative aggregation analysis of DFS for stage I, among which three trials[@b14-ott-8-2033],[@b31-ott-8-2033],[@b35-ott-8-2033] (550 patients) reported available information on stage IB. The combined HR of stages I and IB was 0.68 (*P*=0.002; [Figure 3A](#f3-ott-8-2033){ref-type="fig"}) and 0.55 (*P*=0.02; [Figure 3B](#f3-ott-8-2033){ref-type="fig"}), respectively. An evaluation of DFS for stage IA and II patients could not be conducted due to the limited data. In terms of OS, survival in the chemotherapy group was significantly improved for patients with stage I (HR: 0.74, *P*\<0.00001; [Figure 4A](#f4-ott-8-2033){ref-type="fig"}) and IB (HR: 0.74, *P*=0.0003; [Figure 4B](#f4-ott-8-2033){ref-type="fig"}). There was no statistically significant benefit for stage IA patients (HR: 0.76, *P*=0.43; [Figure 4C](#f4-ott-8-2033){ref-type="fig"}), though there was a positive trend for improved survival in the chemotherapy group. No publication bias was detected by Begg's and Egger's tests. In this analysis, the OS data on stage II patients was not sufficient to perform a reliable analysis.

Subgroup analysis of survival by chemotherapy regimens
------------------------------------------------------

Applicable DFS information was analyzed in nine cisplatin-based trials (1,689 patients) and three single UFT trials (1,298 patients). Cisplatin-based chemotherapy showed results consistent with the overall DFS, which favored postoperative chemotherapy (HR: 0.61, 95% CI, 0.47--0.81, *P*=0.0005; [Figure 3C](#f3-ott-8-2033){ref-type="fig"}). There was evidence of publication bias by Egger's test (*P*=0.029). However, single UFT chemotherapy did not show a DFS benefit with an HR of 1.04 (95% CI, 0.76--1.43, *P*=0.81; [Figure 3D](#f3-ott-8-2033){ref-type="fig"}) without publication bias. OS information was available for analysis in nine cisplatin-based trials (1,854 patients) and five single UFT trials (1,802 patients). Compared with control groups, both cisplatin-based (HR: 0.75, *P*\<0.0001; [Figure 4D](#f4-ott-8-2033){ref-type="fig"}) and single UFT (HR: 0.72, *P*=0.002; [Figure 4E](#f4-ott-8-2033){ref-type="fig"}) chemotherapy showed survival benefits in the combined OS analysis. Some evidence of publication bias was identified in DFS analysis of cisplatin-based chemotherapy by Begg's (*P*=0.048) and Egger's tests (*P*=0.045). ITC demonstrated that cisplatin-based chemotherapy had a longer DFS than single UFT chemotherapy (HR: 0.587, 95% CI, 0.387--0.89, *P*=0.04), but it failed to show difference of OS between the two regimen types (HR: 1.042, 95% CI, 0.816--1.33, *P*=0.90).

Toxicity analysis
-----------------

The toxicity was assessed in 1,692 (97%) of 1,745 patients assigned to chemotherapy group. One trial did not collect toxicity data.[@b15-ott-8-2033] Grade 3--4 neutropenia, nausea and vomiting, thrombocytopenia, and infection were observed in 16.4%, 10.7%, 2%, and 1.9% of the patients who received cisplatin-based chemotherapy, respectively. Incidence of other adverse effects like sensory neuropathy, anemia, and diarrhea were less than 1%. Incidence of grade 3 or 4 nausea/vomiting and anorexia were observed in 0.8% and 0.7% of the patients who received single UFT chemotherapy, respectively. Only four treatment-related deaths (0.2%) occurred in chemotherapy group (data not shown). These findings indicate that chemotherapy toxicity was mild and well tolerated.

Sensitivity analysis and publication bias
-----------------------------------------

Although we applied a random effects model that took variation across studies into consideration, heterogeneity was still significant in DFS analysis. Therefore, we conducted sensitivity analysis to search for the source of heterogeneity. The findings showed some trials might influence integral heterogeneity, but the results of DFS did not essentially change after excluding these individual trials, so the results reported in this study were stable and acceptable. Publication bias by Begg's and Egger's tests is summarized in [Table 2](#t2-ott-8-2033){ref-type="table"}.

Discussion
==========

As an important adjuvant treatment, the effect of postoperative chemotherapy in NSCLC is an important concern of oncologists. In recent years, several meta-analyses that explored the benefits of postoperative chemotherapy for NSCLC had been published, and the main characteristics are listed in [Table 3](#t3-ott-8-2033){ref-type="table"}. They demonstrated that postoperative chemotherapy was beneficial for NSCLC, but they did not discuss the survival benefit of chemotherapy without radiotherapy in early stage patients. Therefore, this meta-analysis was restricted to postoperative chemotherapy alone and early stage NSCLC.

We found survival advantages of receiving postoperative chemotherapy alone in early NSCLC patients. Subgroup analysis showed that this advantage had statistical significance in stages I and IB but not in stage IA. Similar results were also reported in other meta-analyses. Hamada et al[@b38-ott-8-2033] focused on postoperative chemotherapy with UFT in stage I NSCLC and reported that 5-years OS rate was significantly higher in the chemotherapy group compared to control group (81.5% versus 77.2%, *P*=0.011, HR: 0.74). Bria et al[@b39-ott-8-2033] reported that patients with stage I--III disease who received cisplatin-based chemotherapy had a longer survival than those who underwent surgery alone in all stages including early NSCLC. However, the relative risk (instead of the more frequently used HR) and non-full paper trials in Bria's analysis might influence the accuracy of survival determination. Unlike stages IB and I, we did not observe an OS benefit of chemotherapy for stage IA disease (HR: 0.76, 95% CI, 0.39--1.50). This result was compatible with the Lung Adjuvant Cisplatin Evaluation Collaborative Group,[@b10-ott-8-2033] which performed a trial on cisplatin-based chemotherapy in patients with stage I--III disease. Negative efficacy of postoperative chemotherapy in stage IA was based on only three trials, likely because stage IA patients are rare at initial surgery and these patients are less likely to receive postoperative chemotherapy. These results need to be confirmed in large RCTs.

Consistent with the study conducted by Berghmans et al[@b40-ott-8-2033] we found that both cisplatin-based and single UFT chemotherapy significantly improved OS. But their analysis included two trials presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, which might cause the imprecise effect because of insufficient data (ie, randomization procedures, patient allocation, or trials quality). A meta-analysis including stage I--III patients conducted by Hotta et al[@b4-ott-8-2033] also suggested that both cisplatin-based chemotherapy (HR: 0.89, *P*=0.012) and single UFT (HR: 0.80, *P*=0.015) significantly improved OS. This postoperative chemotherapy benefit in OS was also confirmed by Sedrakyan et al.[@b41-ott-8-2033] These data strengthened our results regarding subgroup analysis of different chemotherapy regimens. Importantly, advantages of cisplatin-based and single UFT chemotherapy identified in our study were superior to those reported in other meta-analyses. It should be noted that the above three meta-analyses did not investigate the effect of postoperative chemotherapy on DFS, while we did it. Our results demonstrated that cisplatin-based chemotherapy significantly improved DFS, but single UFT chemotherapy did not. In addition, we provided the first evidence that cisplatin-based chemotherapy was better than single UFT chemotherapy with regard to DFS for early NSCLC patients by ITC software, but the OS benefits were similar for the two kinds of chemotherapy regimens. However, this finding should be interpreted carefully, because all the UFT trials were conducted in Japan and this agent was not extensively administrated in other areas. In addition, the small number of studies was not sufficient to draw exact conclusions. More RCTs about postoperative UFT chemotherapy for NSCLC outside Japan should be conducted in the future.

The PORT meta-analysis[@b16-ott-8-2033] indicated that postoperative radiotherapy had a detrimental effect on survival, particularly for early stage NSCLC patients. So, it was unreasonable that postoperative radiotherapy was included in the meta-analysis of postoperative chemotherapy, because it might increase chemotherapy toxicities. However, these meta-analyses listed in [Table 3](#t3-ott-8-2033){ref-type="table"} still permitted postoperative radiotherapy in selecting eligible trials, including the study conducted by NSCLC Meta-analyses Collaborative Group.[@b19-ott-8-2033] For the reasons mentioned above, trials with postoperative radiotherapy were excluded from our meta-analysis to avoid accumulated harmful effects.

It should be noted that publication bias is a potential threat to the validity of our meta-analysis. Heterogeneity decreased after excluding studies by Endo et al[@b11-ott-8-2033] and Roselli et al[@b14-ott-8-2033] from the overall DFS analysis; Roselli et al[@b14-ott-8-2033] and Felip et al[@b36-ott-8-2033] from stage I analysis; and Strauss et al[@b35-ott-8-2033] and Felip et al[@b36-ott-8-2033] from cisplatin-based chemotherapy analysis. The 5-year OS rate of control group was 75% in the study by Endo et al[@b11-ott-8-2033] which was higher than the expected survival rate (50%) due to the majority of IA patients. So, the number of eligible cases (n=122) in trial design was too small to detect a difference. The study by Felip et al[@b36-ott-8-2033] was conducted in several centers and the compliance was only 51%. The study by Strass et al[@b35-ott-8-2033] stopped before pre-assignment time. In addition, a subset of the patients underwent minimal resection but not complete resection in the study by Roselli et al.[@b14-ott-8-2033] Additionally, these trials that had large age difference with others were excluded from overall heterogeneity analysis. The value of *I*^2^ was still \>50% after excluding studies with minimum[@b29-ott-8-2033] and maximum age,[@b14-ott-8-2033] and two studies with age \<60 years.[@b29-ott-8-2033],[@b33-ott-8-2033] Therefore, age did not substantially influence heterogeneity of DFS. These factors may explain the different results among the studies.

Several limitations in this meta-analysis should be pointed out. Firstly, heterogeneity existed in some of the DFS results. Some factors, such as variable ethnic origin, TNM stage, age, and drug administration, could explain some of the difference among the studies. Secondly, we confirmed the superiority of postoperative chemotherapy alone in early stage NSCLC patients, but only 51%--86% of patients completed their predesigned chemotherapy regimens and there was an obvious gap of compliance among all trials. Further efforts to improve compliance without increasing toxicities are essential. Lastly, only articles published in full papers and English language were included in this meta-analysis. This selection might induce a potential publication bias, because positive studies are more likely and easier to be published than negative ones.

Conclusion
==========

In conclusion, our meta-analysis demonstrates the positive efficacy of postoperative chemotherapy alone in stage I--II, I, and IB NSCLC with mild toxicity, but a significant benefit was not found in IA patients. Meanwhile, this meta-analysis also indicates that efficacy of cisplatin-based chemotherapy is comparable to single UFT chemotherapy in OS, but better than single UFT chemotherapy in DFS; however, further studies are needed to verify these findings in clinical practice. In view of few trials that have assessed the effects of postoperative chemotherapy alone in stage IA and II patients, we suggest that more trials should be conducted to confirm the effectivity of postoperative chemotherapy in stage IA and II NSCLC patients in future.
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![Forest plots of pooled results on DFS (**A**) and OS (**B**) comparing chemotherapy and control groups.\
**Abbreviations:** CI, confidence interval; DFS, disease-free survival; IV, inverse variance; OS, overall survival; SE, standard error.](ott-8-2033Fig2){#f2-ott-8-2033}

![Subgroup analysis of DFS comparing chemotherapy and control groups.\
**Notes:** (**A**) Subgroup analysis of stage I. (**B**) Subgroup analysis of stage IB. (**C**) Subgroup analysis of cisplatin-based chemotherapy. (**D**) Subgroup analysis of single-agent UFT therapy.\
**Abbreviations:** CI, confidence interval; DFS, disease-free survival; IV, inverse variance; SE, standard error; UFT, tegafur--uracil.](ott-8-2033Fig3){#f3-ott-8-2033}

![Subgroup analysis of OS comparing chemotherapy and control groups.\
**Notes:** (**A**) Subgroup analysis of OS in stage I. (**C**) Subgroup analysis of OS in stage IA. (**B**) Subgroup analysis of OS in stage IB. (**D**) Subgroup analysis of OS in cisplatin-based chemotherapy. (**E**) Subgroup analysis of OS in a single-agent UFT therapy. \*Used random effect models.\
**Abbreviations:** CI, confidence interval; IV, inverse variance; OS, overall survival; SE, standard error; UFT, tegafur--uracil.](ott-8-2033Fig4){#f4-ott-8-2033}

###### 

Baseline characteristics of the included RCTs in this meta-analysis

  Researches                        Stage   Number   Age (years)   Chemotherapy regimens   Compliance (%)   Median follow-up (months)                                                                        
  --------------------------------- ------- -------- ------------- ----------------------- ---------------- ----------------------------------------------------------------------------------------- ------ -------
  Niiranen et al[@b29-ott-8-2033]   I--II   54       56            57                      59               C (400 mg/m^2^) + A (40 mg/m^2^) + P (40 mg/m^2^), 6 cycles                               57.4   120
  Feld et al[@b28-ott-8-2033]       I       136      133           NR                      NR               C (400 mg/m^2^) + A (40 mg/m^2^) + P (60 mg/m^2^), 4 cycles                               53     45.6
  Wada et al[@b37-ott-8-2033]       I--II   109      116           63                      62.7             P (80 mg/m^2^) d1 + V (2--3 mg/m^2^) d1, 8+ M (8 mg/m^2^) d1 → UFT (400 mg/day), 1 year   78.8   60
  Mineo et al[@b31-ott-8-2033]      I       33       33            63.3±8.5                64.4±8.4         P (100 mg/m^2^) d1 + E (120 mg/m^2^) d1--3, 6 cycles                                      75.7   ≥60
  Endo et al[@b11-ott-8-2033]       I--II   109      110           63.9                    62.2             UFT (260 mg/m^2^/day or 400 mg/body/day), 2 years                                         63.3   63.5
  Kato et al[@b12-ott-8-2033]       I       491      488           62                      62               UFT (250 mg/m^2^/day), 2 years                                                            61     72/73
  Imaizumi et al[@b32-ott-8-2033]   I       50       50            62.1±7.7                62.5±6.3         P (80 mg/m^2^) d1 + V (3 mg/m^2^) d1, 8+ UFT (400 mg/day), 2 years                        86     NR
  Imaizumi et al[@b32-ott-8-2033]   I       50       50            61.8±8.6                62.5±6.3         UFT (400 mg/day), 2 years                                                                 74     NR
  Nakagawa et al[@b13-ott-8-2033]   I       163      169           62.5                    63.1             UFT (400 mg/day), 1 years                                                                 50.9   75.8
  Park et al[@b33-ott-8-2033]       I       59       59            58.7±6.5                57.9±7.02        M (10 mg/m^2^) d1 + Vb (6 mg/m^2^) d1 + P (100 mg/m^2^) d1--5, 3 or 4 cycles              57.6   87.6
  Nakagawa et al[@b34-ott-8-2033]   I       85       87            60.2                    60.9             UFT (400 mg/day), ≥1 year                                                                 76.7   88.8
  Roselli et al[@b14-ott-8-2033]    I       70       70            64.7±9.9                62.9±9.2         P (100 mg/m^2^) d1 + E (120 mg/m^2^) d1--3, 6 cycles                                      63     NR
  Strauss et al[@b35-ott-8-2033]    I       173      171           61                      62               Pa (200 mg/m^2^) + Ca (6 mg/mL), 4 cycles                                                 86     74
  Felip et al[@b36-ott-8-2033]      I       163      154           64                      64               Pa (200 mg/m^2^) + Ca (6 mg/mL/min), 3 cycles                                             60.9   51
  Butts et al[@b15-ott-8-2033]      I--II   242      240           60.5                    61               Vi (25 mg/m^2^), 16 course + P (50 mg/m^2^) d1 and d8, 4 cycles                           NR     111.6

**Abbreviations:** A, doxorubicin; C, cyclophosphamide; Ca, carboplatin; E, etoposide; M, mitomycin; NR, not reported; P, cisplatin; Pa, paclitaxel; RCTs, randomized control trials; UFT, tegafur--uracil; V, vindesine; Vb, vinblastine; Vi, vinorelbine; d, day.

###### 

Publication bias accessed by Begg's and Egger's tests

                                  Begg's test   Egger's test
  ------------------------------- ------------- --------------
  DFS                                           
   Stage I--II                    0.304         0.029
   Stage I                        0.251         0.065
   Stage IB                       1.000         0.336
   Cisplatin-based chemotherapy   0.118         0.029
   Single UFT chemotherapy        1.000         0.950
  OS                                            
   Stage I--II                    0.112         0.152
   Stage I                        0.087         0.152
   Stage IA                       1.000         0.771
   Stage IB                       0.548         0.187
   Cisplatin-based chemotherapy   0.048         0.045
   Single UFT therapy             0.462         0.402

**Abbreviations:** DFS, disease-free survival; OS, overall survival; UFT, tegafur--uracil.

###### 

Main results of other related meta-analyses

  Meta-analyses                                                 Objects                                                           Radiotherapy   Number   HR (95% CI)         *P*-value           
  ------------------------------------------------------------- ----------------------------------------------------------------- -------------- -------- ------------------- ------------------- ----------
  Hotta et al[@b4-ott-8-2033]                                   Stage I--IV patients                                              Yes            11       5,537               0.87 (0.81--0.94)   0.001
  Subgroup analyses                                                                                                                                                                               
  S versus S + cis-based                                        Yes                                                               8              3,786    0.89 (0.82--0.98)   0.012               
  S versus S + UFT                                              No                                                                5              1,751    0.80 (0.67--0.96)   0.015               
  Sedrakyan et al [@b41-ott-8-2033]                             Stage I--IIIA patients                                            Yes            19       7,200               0.87 (0.81--0.93)   \<0.0001
  S versus S + cis-based                                        Yes                                                               12             NR       0.89 (0.82--0.96)   0.004               
  S versus S + UFT                                              No                                                                7              NR       0.87 (0.81--0.93)   \<0.0001            
  Berghmans et al [@b40-ott-8-2033]                             Stage I--III patients                                             Yes            19       7,644               0.84 (0.78--0.89)   NR
  Subgroup analyses[a](#tfn3-ott-8-2033){ref-type="table-fn"}                                                                                                                                     
  Stage I--II                                                   Yes                                                               10             4,602    0.88 (0.83--0.94)   NR                  
  Stage III                                                     Yes                                                               5              1,481    0.85 (0.69--1.04)   NR                  
  S versus S + cis-based                                        Yes                                                               16             NR       0.86 (0.80--0.92)   NR                  
  S versus S + UFT                                              No                                                                6              NR       0.72 (0.61--0.85)   NR                  
  Hamada et al [@b38-ott-8-2033]                                Stage I patients[b](#tfn4-ott-8-2033){ref-type="table-fn"}        No             6        2,003               0.74 (0.61--0.88)   0.001
  Subgroup analyses[a](#tfn3-ott-8-2033){ref-type="table-fn"}                                                                                                                                     
  IA                                                            No                                                                NR             1,308    0.73 (0.56--0.93)   0.72                
  IB                                                            No                                                                NR             674      0.78 (0.60--1.01)   0.72                
  Pignon et al[@b10-ott-8-2033]                                 Stage I--III patients[c](#tfn5-ott-8-2033){ref-type="table-fn"}   Yes            5        4,584               0.89 (0.82--0.96)   0.005
  Subgroup analyses                                                                                                                                                                               
  Stage IA                                                      Yes                                                               NR             NR       1.40 (0.95--2.06)   NR                  
  Stage IB                                                      Yes                                                               NR             NR       0.93 (0.78--1.10)   NR                  
  Stage II                                                      Yes                                                               NR             NR       0.83 (0.73--0.95)   NR                  
  Stage III                                                     Yes                                                               NR             NR       0.83 (0.72--0.94)   NR                  
  Bria et al [@b39-ott-8-2033]                                  Stage I--III patients[c](#tfn5-ott-8-2033){ref-type="table-fn"}   Yes            20       7,408               0.91 (0.85--0.97)   0.011
  Subgroup analyses[a](#tfn3-ott-8-2033){ref-type="table-fn"}                                                                                                                                     
  Stage I--II                                                   Yes                                                               9              3,774    0.85 (0.79--0.91)   \<0.0001            
  Stage I                                                       Yes                                                               7              1,888    0.88 (0.79--0.98)   0.022               
  Stage III                                                     Yes                                                               6              1,666    0.91 (0.85--0.96)   0.004               
  NSCLC                                                         Stage I--IV patients                                              Yes            34       8,447               0.86 (0.81--0.92)   \<0.0001
  Meta-analyses                                                 Subgroup analyses[a](#tfn3-ott-8-2033){ref-type="table-fn"}                                                                       
  Collaborative                                                 S versus S + cis-based                                            Yes            18       2,620               0.89 (0.82--0.97)   0.006
  Group[@b19-ott-8-2033]                                        S versus S + UFT                                                  No             8        3,848               0.80 (0.71--0.90)   0.001

**Notes:**

Trials included more than one subgroup comparison;

patients received single UFT chemotherapy only;

patients received cisplatin-based chemotherapy only.

**Abbreviations:** HR, hazard ratio; OS, overall survival; CI, confidence interval; S, surgery; UFT, tegafur--uracil; NR, not reported; cis-based, cisplatin-based chemotherapy.

[^1]: These authors contributed equally to this work
